Newbury Pharmaceuticals has received orders for international markets covering shipments during 2023 totalling a value of app. 6.2 MSEK.

“We are pleased to announce an update on our international sales activities. The confirmed orders represent a value of app. 6.2 MSEK with shipments divided across the entire year (2023). These orders provide a solid financial platform and support the sales growth together with the launch of new products in Scandinavia.” Says Mr. Lars Minor, CEO of Newbury.

The international sales activities are conducted by the subsidiary in Switzerland. Newbury focus on the Scandinavian markets, but international sales opportunities contribute to improved sales and profitability.

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

International sales orders for 2023

© Modular Finance, source Nordic Press Releases